Open Access

AGR2 is associated with gastric cancer progression and poor survival

  • Authors:
    • Jun Zhang
    • Yongming Jin
    • Shaonan Xu
    • Jiayin Zheng
    • Qi Zhang
    • Yuanyu Wang
    • Jinping Chen
    • Yazeng Huang
    • Xujun He
    • Zhongsheng Zhao
  • View Affiliations

  • Published online on: January 29, 2016     https://doi.org/10.3892/ol.2016.4160
  • Pages: 2075-2083
  • Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Anterior gradient protein 2 (AGR2) has been reported as a novel biomarker with a potential oncogenic role. However, its association with the prognosis and survival rate of gastric cancer (GC) has not yet been determined. Therefore, the present study aimed to examine the expression and prognostic significance of AGR2 in patients with GC. Immunohistochemistry was used to analyze AGR2 and cathepsin D (CTSD) protein expression in 436 clinicopathologically characterized GC cases and 92 noncancerous tissue samples. AGR2 and CTSD expression were both elevated in GC lesions compared with noncancerous tissues. In 204/436 (46.8%) GC patients, high expression of AGR2 was positively correlated with the expression of CTSD (r=0.577, P<0.01). Furthermore, several clinicopathological parameters were significantly associated with AGR2 expression level, including tumor size, depth of invasion and TNM stage (P<0.05). Using Kaplan‑Meier survival analysis, it was determined that the mean survival time of patients with low levels of AGR2 expression was significantly longer than those with high ARG2 expression (in stages I, II and III; P<0.05). For stage IV disease, no significant difference in survival time was identified. Multivariate survival analysis demonstrated that AGR2 was an independent prognostic factor and was associated in the progression of GC. The findings of the present study indicate that AGR2 expression is significantly associated with location and size of GC, depth of invasion, TNM stage, lymphatic metastasis, vessel invasion, distant metastasis, Lauren's classification, high CTSD expression and poor prognosis. Thus, AGR2 may be a novel GC marker and may present a potential therapeutic target for GC.
View Figures
View References

Related Articles

Journal Cover

March-2016
Volume 11 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang J, Jin Y, Xu S, Zheng J, Zhang Q, Wang Y, Chen J, Huang Y, He X, Zhao Z, Zhao Z, et al: AGR2 is associated with gastric cancer progression and poor survival. Oncol Lett 11: 2075-2083, 2016
APA
Zhang, J., Jin, Y., Xu, S., Zheng, J., Zhang, Q., Wang, Y. ... Zhao, Z. (2016). AGR2 is associated with gastric cancer progression and poor survival. Oncology Letters, 11, 2075-2083. https://doi.org/10.3892/ol.2016.4160
MLA
Zhang, J., Jin, Y., Xu, S., Zheng, J., Zhang, Q., Wang, Y., Chen, J., Huang, Y., He, X., Zhao, Z."AGR2 is associated with gastric cancer progression and poor survival". Oncology Letters 11.3 (2016): 2075-2083.
Chicago
Zhang, J., Jin, Y., Xu, S., Zheng, J., Zhang, Q., Wang, Y., Chen, J., Huang, Y., He, X., Zhao, Z."AGR2 is associated with gastric cancer progression and poor survival". Oncology Letters 11, no. 3 (2016): 2075-2083. https://doi.org/10.3892/ol.2016.4160